Second Sight Medical Products Inc. (NASDAQ:EYES) went up by 11.11% from its latest closing price compared to the recent 1-year high of $4.24. The company’s stock price has collected 8.11% of gains in the last five trading sessions.
Is It Worth Investing in Second Sight Medical Products Inc. (NASDAQ :EYES) Right Now?
Plus, the 36-month beta value for EYES is at 2.62. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for Second Sight Medical Products Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $10.00. EYES currently public float of 28.13M and currently shorts hold a 4.24% ratio of that float. Today, the average trading volume of EYES was 295.85K shares.
EYES’s Market Performance
EYES stocks went up by 8.11% for the week, with a monthly drop of -9.91% and a quarterly performance of 21.95%, while its annual performance rate touched -47.64%. The volatility ratio for the week stands at 6.16% while the volatility levels for the past 30 days are set at 6.46% for Second Sight Medical Products Inc. The simple moving average for the period of the last 20 days is -0.94% for EYES stocks with a simple moving average of 8.40% for the last 200 days.
Analysts’ Opinion of EYES
Many brokerage firms have already submitted their reports for EYES stocks, with Dougherty & Company repeating the rating for EYES by listing it as a “Buy.” The predicted price for EYES in the upcoming period, according to Dougherty & Company is $2 based on the research report published on December 13th of the previous year 2019.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see EYES reach a price target of $21. The rating they have provided for EYES stocks is “Buy” according to the report published on July 06th, 2015.
EYES Trading at -5.63% from the 50-Day Moving Average
After a stumble in the market that brought EYES to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.83% of loss for the given period.
Volatility was left at 6.46%, however, over the last 30 days, the volatility rate increased by 6.16%, as shares sank -5.66% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading unchanged at present.
During the last 5 trading sessions, EYES rose by +8.11%, which changed the moving average for the period of 200-days by -31.51% in comparison to the 20-day moving average, which settled at $2.0100. In addition, Second Sight Medical Products Inc. saw 22.70% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at EYES starting from Williams Gregg, who purchase 3,700 shares at the price of $2.00 back on Jun 13. After this action, Williams Gregg now owns 11,237,047 shares of Second Sight Medical Products Inc., valued at $7,400 using the latest closing price.
Williams Gregg, the Director of Second Sight Medical Products Inc., purchase 3,960 shares at $2.46 during a trade that took place back on Jun 03, which means that Williams Gregg is holding 11,233,347 shares at $9,748 based on the most recent closing price.
Stock Fundamentals for EYES
Equity return is now at value -12.00, with -11.50 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 28.64.